Biotech Updates: Acrivon CLIA Lab, Lilly M&A Spree, Defence Radiopharma COO
Aug 17, 2026
Acrivon launched a CLIA-certified lab. Eli Lilly disclosed over 5 trillion won in M&A and licensing. Defence Therapeutics named a new radiopharmaceutical COO.
News Related to Eli Lilly and Company
Related coverage linked through entity extraction aliases.
CRISPR Technology Advances: Off-Target Benchmark, New Data, and Licensing Deal
Aug 12, 2026
IDT's study showed UNCOVERseq achieved 97.6% sensitivity and 78% precision for CRISPR off-target nomination. Scribe will present new data at ASGCT and EAS, including STX-1150. Watchmaker licensed CRISPR-Cas9 IP for NGS normalization.
Pharma Earnings Roundup: Alnylam, Neurocrine, AbbVie, Merck, Roche Miss Expectations
Aug 11, 2026
Several drugmakers saw shares fall after earnings missed expectations. Alnylam's Amvuttra sales disappointed despite growth; Neurocrine's guidance underwhelmed; AbbVie's Imbruvica and Roche's Vabysmo fell short of consensus.
Lawmakers Probe Drugmakers Over China Clinical Trials as U.S. Seeks to Counter Biotech Rise
Jul 31, 2026
Lawmakers opened national security probes into Merck, AbbVie and others over China drug trials. A survey finds China closing in on U.S. biotech leadership, and HHS launched clinical trial reforms to counter the rise.
Roche Alzheimer's Blood Tests Gain FDA and CE Approvals Amid Medicare Coverage Gap
Apr 22, 2026
Roche's Elecsys pTau181 test received FDA clearance for primary care use, and its Elecsys ApoE4 test earned CE Mark approval. Despite these advances, Medicare does not cover Alzheimer's blood biomarker screenings before symptoms appear, prompting the bipartisan ASAP Act.
UK Regulator Reports 150,000 Adverse Events and 153 Deaths Linked to Weight-Loss Jabs
Aug 08, 2026
UK data links 150+ deaths to weight-loss jabs. A new study finds a vegan diet led to 5.9kg average loss in 4 months vs 6.9kg over 9 months for semaglutide.
Pharma Patent Battles: Bristol Myers, Sanofi, Pfizer File Suits; Sarepta Loses Rehearing
Jul 23, 2026
Bristol Myers Squibb, Sanofi, and Pfizer have filed new patent infringement suits over drugs including Camzyos, Lantus, and abrocitinib, while the Federal Circuit denied Sarepta's rehearing bid in a Regenxbio DNA patent case.
Orforglipron Beats Oral Semaglutide in Type 2 Diabetes Trial; Hair Loss on GLP-1s Addressed
Aug 08, 2026
Orforglipron beat oral semaglutide on blood sugar and weight in type 2 diabetes, with higher discontinuation rates. GLP-1 hair loss is typically temporary telogen effluvium.
Biotech IPOs Surge 55% as Nvidia Exit and ARK Buy Split AI Drug Discovery Stocks
Jul 30, 2026
U.S. biotech IPOs have returned 55% on average this year, crushing the broader IPO market. Nvidia exited Recursion as ARK Invest bought shares, while Revolution Medicines gained 132% on strong pancreatic cancer data.
Revolution Medicines Stock Surges 132% on Daraxonrasib Trial Data
Aug 04, 2026
Revolution Medicines (RVMD) shares up 132% YTD. Daraxonrasib beat chemo in pancreatic cancer (13.2 vs 6.7 months median OS). Company has no marketed products and a $39B valuation.
Omics Markets Projected Strong Growth Across Clinical Trials, Digital PCR Consumables, and Fluidic Samplers
May 08, 2026
Market reports project growth in omics-based clinical trials, Asia digital PCR consumables, and multi-omic fluidic samplers. The clinical trials market is set to reach $47.78B by 2030; fluidic samplers grow to $2.76B by 2036.
GLP-1 Boom: One in Eight U.S. Adults Now Taking Drugs, Driving Manufacturing and Consumer Shifts
Aug 01, 2026
One in eight U.S. adults now takes a GLP-1, and prescriptions among non-diabetics rose 700% since 2019. The market is projected to reach $200 billion by 2030, driving manufacturing investments and consumer food shifts.
AI Reshapes Cardiovascular Medicine: $1.4B+ Investments and New Diagnostics
Jul 10, 2026
AI is transforming cardiovascular medicine: $1.4B+ in investments, a new cardiac biomarker sensor, and stroke-imaging software in 2,500+ hospitals. FDA, EMA, and PMDA are opening clearer regulatory pathways.
Novo Nordisk Partners With OpenAI as AI Drug Discovery Gains Momentum
Jul 07, 2026
Novo Nordisk partners with OpenAI to speed drug discovery, with pilots by 2026. AI is moving beyond hype into pharma R&D, reflected in major collaborations and new FDA guidance.
FDA Launches PreCheck and Animal Drug Pilots to Boost US Manufacturing
Jul 24, 2026
The FDA launched two pilots to boost domestic manufacturing: PreCheck selected seven companies for earlier engagement, and a CVM pilot prioritizes animal drug applications with US-made ingredients.
FDA Restricts Compounded GLP-1 Drugs as Weight-Loss Pill Race Heats Up
Jul 21, 2026
The FDA moved to exclude semaglutide, tirzepatide and liraglutide from its 503B compounding list. Eli Lilly won U.S. approval for its oral pill Foundayo, and Novo Nordisk sued Lilly over allegedly misleading weight-loss ads.
Oncology Pipeline Roundup: Lilly's Retevmo Meets Endpoint, Merck Halts MK-6837, Tango Combo Shows Promise
Jul 18, 2026
Eli Lilly's Retevmo met the primary endpoint in a Phase III lung cancer trial, Merck discontinued its TROP2 ADC MK-6837, and a Tango/Revolution combination showed benefit in pancreatic cancer.
CAM Use Tied to Higher Breast Cancer Death Risk; New Molecule Shows Promise Against Triple-Negative Tumors
Jul 29, 2026
A JAMA Oncology study finds breast cancer patients using complementary and alternative medicine face a higher risk of death. A new molecule SU212 shows promise against triple-negative breast cancer, and global breast cancer cases are projected to rise to 3.5 million by 2050.
AI in Drug Discovery Market Forecasts Diverge: $17.56B and $2.29B by 2031
Jul 22, 2026
New reports project AI in drug discovery at $17.56B by 2031 (28.1% CAGR) or $2.29B by 2031 (12.49% CAGR). North America led in 2025, oncology topped therapy areas, and talent shortages persist.
Biotech Pipeline Advances: Can-Fite at BIO 2026, Peptide Candidates Top 2,000, Arrowhead RNAi in Phase 3
Jun 22, 2026
Can-Fite will present late-stage pipeline at BIO 2026; GlobalData counts over 2,000 peptides in development with $91.38bn 2025 sales; Arrowhead's RNAi pipeline has two Phase 3 programs.